Navigation Links
Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation
Date:8/27/2008

fort and convenience.

Alexza has five product candidates in active clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed enrollment of its first Phase 3 clinical trial. A second Phase 3 clinical trial was initiated in July 2008. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing and AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches is in Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated presentations will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
2. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
3. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
4. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
5. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
6. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
9. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
10. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
11. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15
... , DARTMOUTH, NS , July 12 /PRNewswire/ - ... Omega-3, EPA/DHA, food and dietary supplement ingredients, announces today the acquisition ... Essentials (GAT) Omega-3 microencapsulation-emulsion technology. , ... As a result of the agreement, ONC acquired ...
... July 12, 2010 Points to,Novel Pathway for Drug Discovery, ... Aortic Aneurysm, Heart Attack and,PAD , ... Scientists at deCODE genetics and academic colleagues ... and North America today,report the discovery of a common single-letter ...
... , , ... Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing ... clinical advisory panel (the "Panel"). , , ... Panel of international experts with special expertise in ovarian cancer has been charted ...
Cached Biology Technology:Ocean Nutrition Canada Announces Acquisition of Exclusive License to GAT Food Essentials, Omega-3 Microencapsulation-Emulsion Technology 2Ocean Nutrition Canada Announces Acquisition of Exclusive License to GAT Food Essentials, Omega-3 Microencapsulation-Emulsion Technology 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 2deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 4Quest PharmaTech Announces Formation of Clinical Advisory Panel 2Quest PharmaTech Announces Formation of Clinical Advisory Panel 3
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/20/2015)... -- Acuity Market Intelligence,s latest research "The Global Biometrics ... Privacy" forecasts that between 2014 and 2020 nearly ... to smart mobile devices by 2.2 billion mobile ... to generate more than $67.9 billion in total ...    "Biometrics is at the center ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... types are essential for studies of their development ... A Laboratory Manual provides step-by-step protocols for isolating ... them under conditions that closely resemble those in ... dissect the brain, spinal cord, and other tissues; ...
... Did you know that crystals form the basis for the penetrating ... the future in solar energy technology? Crystals are at the ... formed naturally, but manufactured to form alloys, such as indium gallium ... LEDs, for illumination in the visible range, and of laser diodes ...
... grams of essential amino acids taken twice daily for a week ... mean age 69, recover faster and with much less muscle atrophy ... detailed in a paper now online ahead of print in the ... -- could spell relief and speed recovery for a growing population ...
Cached Biology News:ASU, Georgia Tech create breakthrough for solar cell efficiency 2Oregon researchers say supplement cuts muscle loss in knee replacements 2Oregon researchers say supplement cuts muscle loss in knee replacements 3Oregon researchers say supplement cuts muscle loss in knee replacements 4
Mouse monoclonal antibody raised against a partial recombinant ALPK3. NCBI Entrez Gene ID = ALPK3...
Mouse monoclonal antibody raised against a partial recombinant MYO7A. NCBI Entrez Gene ID = MYO7A...
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Mouse monoclonal antibody raised against a partial recombinant ENTPD5. NCBI Entrez Gene ID = ENTPD5...
Biology Products: